Canadian Cancer Trials Group Bulletins


Recent Publications

Canadian Cancer Trials Group MA.14 -- A Randomized Trial of Antiestrogen Therapy versus Combined Antiestrogen and Octreotide Lar Therapy in the Adjuvant Treatment of Breast Cancer in Post-Menopausal Women

Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O'Reilly SE, Wilson CF, Han L, Piura E, Whelan TJ, Pollak MN. Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: Canadian Cancer Trials Group MA.14 (ONLINE). J Clin Oncol 2011.


Canadian Cancer Trials Group OV.17 (EUDRACT #2004-004456-39) -- A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (Caelyx) and Carboplatin vs Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Cancer in Late Relapse (> 6 months): GCIG Calypso Study

Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J, Petru E, Reed N, Gebski V, Pujade-Lauraine E, Lord S, Simes RJ, Friedlander M. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Br J Cancer 105: 360-5, 2011.